Tag: tofacitinib market growth

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

At What Rate is the Tofacitinib Market Predicted to Expand Between 2024 and 2033?

In past few years, the market size of tofacitinib has witnessed accelerated growth. The value is anticipated to rise from $2.76 billion in 2023 to $3.12 billion in 2024, which accounts for a compound annual growth rate (CAGR) of 13.0%. The notable expansion during the historic period is credited to its clinical effectiveness and trials, endorsement by regulatory entities, escalation in occurrence of specific conditions, physicians’ prescribing habits, and the acceptability among patients.

The market for tofacitinib is predicted to experience significant expansion in the coming years, with an anticipated market value of $5.02 billion in 2028 and a compound annual growth rate (CAGR) of 12.7%. This growth during the forecast period can be linked to broadened indications, initiatives to access the market, a competitive environment, practical evidence, and focus on patient-centric healthcare. Future trends predicted during this forecast period include an emphasis on treating pediatric rheumatoid arthritis, the use of tofacitinib for skin conditions, strategic cooperation and partnerships, incorporation of real-world evidence into treatment guidelines, and a focus on individualized medicine strategies.

Claim Your Free Sample of the Global Tofacitinib Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=10779&type=smp

What Forces Are Boosting the tofacitinib Market’s Growth?

An upward trend in the occurrence of rheumatoid arthritis is anticipated to accelerate the expansion of the tofacitinib market. Rheumatoid arthritis, an autoimmune disease marked by inflammation, affects various body parts, including hands, feet, several other joints, and internal organs. Tofacitinib drugs work by stopping the Janus kinase enzymes from taking part in the inflammation that causes rheumatoid arthritis symptoms. As an illustration, according to the National Arthritis Data Workgroup, a group of epidemiology experts based in the US, it was reported that over 52.5 million American adults (equating to more than 22% of the population) were diagnosed with arthritis or a similar rheumatic condition in February 2022. By 2030, the number of adults aged 18 and older suffering from arthritis is expected to hit 67 million. Therefore, the increasing incidence of rheumatoid arthritis is fuelling the expansion of the tofacitinib market.

What Key Segments Make Up the Tofacitinib Market?

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant

2) By Strength: 5mg, 10mg, 11mg, 22mg

3) By Route Of Administration: Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications

What Are the Latest Trends Impacting the Tofacitinib Market?

The emergence of product innovation is a prominent trend within the tofacitinib market. To maintain their market stronghold, primary companies in this industry are progressing towards the development of innovative products. For example, in December 2021, Pfizer Inc., a pharmaceutical and biotechnology corporation based in the US, announced its supplemental New Drug Application (sNDA) approval by the U.S. Food and Drug Administration (FDA) for its tofacitinib-based drugs; XELJANZ and XELJANZ XR. It’s worth noting that XELJANZ stands as the first-ever and sole Janus kinase (JAK) inhibitor approved in the US to treat five immuno-inflammatory illnesses. A Phase 3 study involving randomized, double-masked, placebo-controlled comparisons of the safety and efficacy of 5 mg tofacitinib, administered twice daily versus a placebo to 269 adult patients suffering from active AS laid the groundwork for approving XELJANZ for AS treatment.

Order Now for Fast Delivery of Your Tofacitinib Market Report!

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

What Regions Are Dominating the Tofacitinib Market Growth?

North America was the largest region in the tofacitinib market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Tofacitinib Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the tofacitinib market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Tofacitinib Market Include

1. Tofacitinib Market Executive Summary

2. Tofacitinib Market Segments

3. Tofacitinib Market Size And Template Market Growth Rate

4. Key Tofacitinib Market Trends

5. Major Tofacitinib Market Drivers

……

25. Key Mergers And Acquisitions In The Tofacitinib Market

26. Top Tofacitinib Companies

27. Tofacitinib Market Opportunities And Strategies

28. Tofacitinib Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Circulating Tumor Cells Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Chimeric Antigen Receptor T (CAR-T) Cells Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chimeric-antigen-receptor-t-car-t-cells-global-market-report

Oilseeds Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oilseeds-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The tofacitinib market has experienced rapid growth in recent years, driven by various factors such as clinical efficacy, regulatory approvals, and rising incidences of targeted conditions. With promising growth projections and emerging trends, the market landscape is evolving dynamically.

Market Size and Growth Projections

• The tofacitinib market size is poised for expansion, growing from $2.76 billion in 2023 to $3.12 billion in 2024 at a CAGR of 13.0%.
• Forecasts indicate further growth to $5.02 billion by 2028, with a CAGR of 12.7%, driven by expanded indications and market access initiatives.

Rising Rheumatoid Arthritis Prevalence Fuels Market Growth

• The prevalence of rheumatoid arthritis, an autoimmune inflammatory disorder, is a significant driver of the tofacitinib market.
• With over 52.5 million adult Americans diagnosed with arthritis or related conditions, the demand for effective treatments like tofacitinib is on the rise.
• Major companies operating in the tofacitinib market include Pfizer Inc., Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., among others, contributing to market growth through innovative products and strategic initiatives.

Read More On The Tofacitinib Market Report 2024 – https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Innovation Drives Tofacitinib Market With Novel Products

• Product innovation is a key trend shaping the tofacitinib market landscape, with companies investing in the development of novel therapies.
• Pfizer Inc., for instance, received FDA approval for supplemental New Drug Application (sNDA) for tofacitinib-based medications XELJANZ and XELJANZ XR, marking significant progress in treatment options.
• Strategic acquisitions, such as Pfizer’s acquisition of Arena Pharmaceuticals for $6.7 billion in March 2022, further enrich the market landscape with potential drugs for various therapeutic areas.

Market Segmentation and Regional Insights

• The tofacitinib market is segmented by drug class, strength, route of administration, distribution channel, and application.
• North America emerged as the largest region in the tofacitinib market in 2023, while Asia-Pacific is projected to witness the fastest growth in the forecast period.

Conclusion: Navigating Market Opportunities
The tofacitinib market presents significant opportunities for stakeholders amidst evolving trends and growth prospects. As the market continues to expand, fueled by rising disease prevalence and innovations in treatment options, stakeholders must leverage strategic collaborations, invest in research and development, and focus on personalized medicine approaches. By embracing these strategies, stakeholders can navigate the dynamic landscape of the tofacitinib market and contribute to improving patient outcomes and addressing unmet medical needs effectively.

Request for A Sample Of The Global Tofacitinib Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=10779&type=smp